The application of diagnostic and therapeutic radionuclides in nuclear medicine has grown significantly and has translated into the increased interest in radionuclide generators and their development. Ra and its shorter-lived daughters, Pb and Bi, are very interesting radionuclides from Targeted Alpha Therapy point of view for treatment of small cancers or metastatic forms. The purpose of the present work was to develop a simple generator for rapid elution of carrier-free Ra from U or Th sources by radiochemical separation based on extraction chromatography with the utilization of a home-made material. The bis(2-ethylhexyl) hydrogen phosphate (HDEHP) extractant was immobilized on polytetrafluroethylene (PTFE) grains and its ability to selectively adsorb U and Th, with simultaneous high elution recovery of Ra, was checked over few years. The Ra was quantitatively eluted with small volume (3-5 mL) of 0.1 M HNO with low breakthrough (<0.005%) and was used for further milking of Bi and Pb from DOWEX 50WX12 by 0.75 M and 2.0 M HCl, respectively. The elaborated here methods allowed high recovery of Ra, Pb and Bi radionuclides and their application in radiolabeling of various biomolecules.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.apradiso.2021.109655 | DOI Listing |
JCO Clin Cancer Inform
January 2025
SimBioSys Inc, Chicago, IL.
Purpose: Perfusion modeling presents significant opportunities for imaging biomarker development in breast cancer but has historically been held back by the need for data beyond the clinical standard of care (SoC) and uncertainty in the interpretability of results. We aimed to design a perfusion model applicable to breast cancer SoC dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) series with results stable to low temporal resolution imaging, comparable with published results using full-resolution DCE-MRI, and correlative with orthogonal imaging modalities indicative of biophysical markers.
Methods: Subsampled high-temporal-resolution DCE-MRI series were run through our perfusion model and resulting fits were compared for consistency.
J Chromatogr A
February 2025
Dalton Nuclear Institute, The University of Manchester, Oxford Road, Manchester M13 9PL, UK; Department of Mechanical, Aerospace & Civil Engineering, The University of Manchester, Oxford Road, Manchester M13 9PL, UK.
Mass spectroscopy and microfluidic technology, when combined, offer significant advantages in radiochemical analysis sample volume and cost reduction. A microfluidic device designed for efficiency has been developed. This device separates uranium from key trace elements by utilising UTEVA® chromatographic resins and nitric acid solutions of different concentrations for adsorption and recovery.
View Article and Find Full Text PDFIndian J Nucl Med
November 2024
Department of Nuclear Medicine and Molecular Imaging, Homi Bhabha Cancer Hospital and Mahamana Pandit Madan Mohan Malaviya Cancer Centre, Tata Memorial Centre, Homi Bhabha National Institute, Varanasi, Uttar Pradesh, India.
Background: Prostate-specific membrane antigen (PSMA) has shown to be a promising agent for prostate cancer imaging under PET-CT. With the automation in radiolabeling with 68Ga, using iTG 68Ge/68Ga generator, it has helped introduce various new diagnostic agents and achieve good manufacturing practices (GMP) simultaneously. However, before any radiopharmaceutical is put into clinical usage, it should always be checked for its radiochemical purity and other quality parameters before injecting in the patient.
View Article and Find Full Text PDFJ Nucl Med
January 2025
Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, Maryland; and.
The treatment regimen for [Lu]Lu-prostate-specific membrane antigen (PSMA) 617 therapy follows that of chemotherapy: 6 administrations of a fixed activity, each separated by 6 wk. Mathematic modeling can be used to test the hypothesis that the current treatment regimen for a radiopharmaceutical modality is suboptimal. A mathematic model was developed to describe tumor growth during [Lu]Lu-PSMA therapy.
View Article and Find Full Text PDFIn Vivo
December 2024
Gyula Petrányi Doctoral School of Clinical Immunology and Allergology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
Background/aim: Angiogenesis imaging has been a valuable complement to metabolic imaging with 2-deoxy-2-[F]fluoroglucose (FDG). In our longitudinal study, we investigated the tumour heterogeneity and the relationship between FDG and [Ga]Ga-NODAGA-c(RGDfK) (RGD) accumulation in breast cancer xenografts.
Materials And Methods: Two groups of cell lines, a fast-growing (4T1) and a slow-growing cell line (MDA-MB-HER2+), were inoculated into SCID mice.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!